Policy Development
Source: Cytiva
The FDA has issued guidance to support the development of cell and gene therapy products. There is guidance development based on commitments under PDUFA VII and CBER guidance agenda. Here, BioMarin's Nimi Chhina details how best to approach and support policy development in cell and gene therapy.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Cytiva
This website uses cookies to ensure you get the best experience on our website. Learn more